Kansas CRO Vince & Associates, fresh from its private equity buyout, has expanded its endoscopy capabilities, beefing up its technology to attract more early-phase studies of gastrointestinal therapies.
The company is cutting the ribbon on an endoscopy suite within its 90-bed clinical pharmacology unit, and the CRO has recruited a group of board-certified gastroenterologists to join its ranks and get the new segment rolling, CEO Brad Vince said.
"This investment reaffirms our dedication to providing research expertise in response to increasing demand for conducting clinical research in patient populations during early development, which often requires more specialized techniques," Vince said in a statement. "The endoscopy suite and additional medical expertise significantly broaden the clinical research capabilities we are able to offer our clients."
Vince & Associates was among the many mid-size CROs carving out space in a consolidating market when Altasciences snatched it up for an undisclosed sum in May. The equity group also owns Canadian CRO Algorithme Pharma, which focuses on early-stage compounds.
- read the announcement